Revance Therapeutics Q3 2024 Earnings Report

Revance Therapeutics EPS Results

• Actual EPS: -$0.37
• Consensus EPS: -$0.35
• Beat/Miss: Missed by -$0.02
• One Year Ago EPS: N/A

Revance Therapeutics Revenue Results

• Actual Revenue: $59.88 million
• Expected Revenue: $67.73 million
• Beat/Miss: Missed by -$7.85 million
• YoY Revenue Growth: N/A

Revance Therapeutics Announcement Details

• Quarter: Q3 2024
• Date: 11/7/2024
• Time: N/A
• Conference Call Date: Thursday, November 7, 2024
• Conference Call Time: 4:00PM ET

Revance Therapeutics (NASDAQ:RVNC), a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.